Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2016 Oct 11

PMID 27721336

Citations 8

Authors

Vladimir V Zarubaev

Angelica V Garshinina

Nelly A Kalinina

Anna A Shtro

Svetlana V Belyaevskaya

Alexander V Slita

Vladimir E Nebolsin

Oleg I Kiselev

Affiliations

Soon will be listed here.

Abstract

Respiratory viral infections constitute the most frequent reason for medical consultations in the World. They can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions such as pneumonia. In particular, in serious cases influenza A leads to pneumonia, which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and the elderly. In the present study, we show a protective effect of the low-molecular weight compound Ingavirin (6-[2-(1H-imidazol-4-yl)ethylamino]-5-oxohexanoic acid) against influenza A (H1N1) virus, human parainfluenza virus and human adenovirus infections in animals. Mortality, weight loss, infectious titer of the virus in tissues and tissue morphology were monitored in the experimental groups of animals. The protective action of Ingavirin was observed as a reduction of infectious titer of the virus in the lung tissue, prolongation of the life of the infected animals, normalization of weight dynamics throughout the course of the disease, lowering of mortality of treated animals compared to a placebo control and normalization of tissue structure. In case of influenza virus infection, the protective activity of Ingavirin was similar to that of the reference compound Tamiflu. Based on the results obtained, Ingavirin should be considered as an important part of anti-viral prophylaxis and therapy.

Citing Articles

IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents.

Wesolowski R, Fish B, Eibl M, Bahr S, Munjal Mehta S, Czajkowski M Int J Radiat Biol. 2024; 101(1):1-14.

PMID: 39531584 PMC: 11698650. DOI: 10.1080/09553002.2024.2425312.

Imidazolyl Ethanamide Pentandioic Acid (IEPA) as Potential Radical Scavenger during Tumor Therapy in Human Hematopoietic Stem Cells.

Pfau L, Glasow A, Seidel C, Patties I Molecules. 2023; 28(5).

PMID: 36903253 PMC: 10004037. DOI: 10.3390/molecules28052008.

Insight into the Hantaan virus RNA-dependent RNA polymerase inhibition using in-silico approaches.

Faisal S, Badshah S, Sharaf M, Abdalla M Mol Divers. 2022; 27(6):2505-2522.

PMID: 36376718 PMC: 9663193. DOI: 10.1007/s11030-022-10567-6.

Anti-Influenza Effect of Nanosilver in a Mouse Model.

Kiseleva I, Al Farroukh M, Skomorokhova E, Rekstin A, Bazhenova E, Magazenkova D Vaccines (Basel). 2020; 8(4).

PMID: 33202939 PMC: 7712555. DOI: 10.3390/vaccines8040679.

7-Imidazolyl-substituted 4'-methoxy and 3',4'-dimethoxy-containing polyfluoroflavones as promising antiviral agents.

Shcherbakov K, Artemyeva M, Burgart Y, Saloutin V, Volobueva A, Misiurina M J Fluor Chem. 2020; 240:109657.

PMID: 33071313 PMC: 7547832. DOI: 10.1016/j.jfluchem.2020.109657.

References

Dawson T, Beck M, Kuziel W, Henderson F, Maeda N . Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol. 2000; 156(6):1951-9. PMC: 1850091. DOI: 10.1016/S0002-9440(10)65068-7. View

Kolobukhina L, Merkulova L, Shchelkanov M, Burtseva E, Isaeva E, Malyshev N . [Efficacy of ingavirin in adults with influenza]. Ter Arkh. 2009; 81(3):51-4. View

Abed Y, Boivin G . Treatment of respiratory virus infections. Antiviral Res. 2006; 70(2):1-16. PMC: 7114251. DOI: 10.1016/j.antiviral.2006.01.006. View

Shishkina L, Nebolsin V, Kabanov A, Skarnovich M, Mazurkova N, Sergeev A . [In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v]. Zh Mikrobiol Epidemiol Immunobiol. 2011; (2):93-6. View

Chan P, Connell N, Gabonay A, Westley B, Larkin J, LaRosa S . Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect. 2010; 16(10):1576-8. DOI: 10.1111/j.1469-0691.2010.03212.x. View

Loginova S, Borisevich S, Maksimov V, Bondarev V . [Toxicity estimation of unspecific medicinal antiviral agents for prophylaxis and therapy of hazard and especially hazard viral infections]. Antibiot Khimioter. 2009; 54(3-4):11-4. View

Krug R, Aramini J . Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci. 2009; 30(6):269-77. PMC: 2964876. DOI: 10.1016/j.tips.2009.03.002. View

Hayden F . Combination antiviral therapy for respiratory virus infections. Antiviral Res. 1996; 29(1):45-8. DOI: 10.1016/0166-3542(95)00914-0. View

To K, Hung I, Li I, Lee K, Koo C, Yan W . Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010; 50(6):850-9. PMC: 7107930. DOI: 10.1086/650581. View

10.

Moscona A . Oseltamivir resistance--disabling our influenza defenses. N Engl J Med. 2005; 353(25):2633-6. DOI: 10.1056/NEJMp058291. View

11.

Hagiwara K, Kondoh Y, Ueda A, Yamada K, Goto H, Watanabe T . Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem Biophys Res Commun. 2010; 394(3):721-7. DOI: 10.1016/j.bbrc.2010.03.058. View

12.

Alleva L, Cai C, Clark I . Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza. Evid Based Complement Alternat Med. 2009; 7(4):501-10. PMC: 2892358. DOI: 10.1093/ecam/nep152. View

13.

Greer C, Zhou F, Goodsell A, Legg H, Tang Z, zur Megede J . Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. Scand J Immunol. 2007; 66(6):645-53. DOI: 10.1111/j.1365-3083.2007.02019.x. View

14.

Hauge S, Dudman S, Borgen K, Lackenby A, Hungnes O . Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis. 2009; 15(2):155-62. PMC: 2657637. DOI: 10.3201/eid1502.081031. View

15.

Dharan N, Gubareva L, Meyer J, Okomo-Adhiambo M, McClinton R, Marshall S . Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009; 301(10):1034-41. DOI: 10.1001/jama.2009.294. View

16.

Zarubaev V, Krivitskaia V, Nebolsin V, Kiselev O . [Experimental investigation of Ingavirin antiviral activity against human parainfluenza virus]. Antibiot Khimioter. 2010; 55(7-8):13-6. View

17.

Henrickson K . Parainfluenza viruses. Clin Microbiol Rev. 2003; 16(2):242-64. PMC: 153148. DOI: 10.1128/CMR.16.2.242-264.2003. View

18.

. Influenza activity--United States and worldwide, May 18-September 19, 2008. MMWR Morb Mortal Wkly Rep. 2008; 57(38):1046-9. View

19.

Loginova S, Borisevich S, Lykov M, Vedenina E, Borisevich G, Bondarev V . [In vitro efficacy of ingavirin against the Mexican pandemic subtype H1N1 of influenza A virus, strains A/California/04/2009 and A/California/07/2009]. Antibiot Khimioter. 2009; 54(3-4):15-7. View

20.

Zambon M . Epidemiology and pathogenesis of influenza. J Antimicrob Chemother. 2000; 44 Suppl B:3-9. DOI: 10.1093/jac/44.suppl_2.3. View